Michael Makris/LinkedIn
Oct 30, 2025, 03:53
Michael Makris on Biomarin’s Decision to Divest Roctavian
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”Important.
Biomarin, the only manufacturer of an approved hemophilia A gene therapy has decided to divest Roctavian and remove it from their portfolio.
They plan to sell it on to a more established hemophilia company, if they can find a buyer.
The problems have been the high cost and limited durability.
This is a sad turn of events but not surprising to anybody who follows the field.
We suspected that sales were poor, but not this poor, as indicated in their press release.
This is their press release.”
Stay updated with Hemostasis Today.
-
Feb 2, 2026, 17:54Danny Gaskin: Nominations are Open for the BBTS Transfusion Practitioner Special Interest Group Award 2026
-
Feb 2, 2026, 17:44Important Webinar on Care for Patients with iTTP – ISTH
-
Feb 2, 2026, 17:21Tagreed Alkaltham: Some Risks Don’t Look Like Risks in Healthcare
-
Feb 2, 2026, 17:16Sifat Jubaira: Effect of Prolonged Tourniquet Application
-
Feb 2, 2026, 17:14Vivek Mahto: Understanding Deep Vein Thrombosis – Causes, Symptoms, and Prevention
-
Feb 2, 2026, 17:08Tareq Abadl: Heparin vs Warfarin
-
Feb 2, 2026, 17:07Mary Cushman: New Research on Aspirin Use in Pregnancy and Stroke Risk in Offspring
-
Feb 2, 2026, 16:52Aravind Palraj: Young Stroke is Never Just Stroke
-
Feb 2, 2026, 16:48Seyed Mohsen Jahromi Moghadam: Antithrombotic Therapy After Transcatheter Structural Heart Interventions